Pixuvri

Servier acquires lymphoma drug Pixuvri from CTI BioPharma
Pharmaceutical Business Review
Tue, 10/1/19 - 10:50 pm
Pixuvri
Servier
CTI BioPharma
M&A
lymphoma
Years in the unmaking, CTI’s Pixuvri fails a pivotal PhIII combo study for lymphoma — can it remain on the market?
Endpoints
Mon, 07/9/18 - 12:00 pm
CTI Pharma
Pixuvri
B-cell non-Hodgkin lymphoma
clinical trials
$4 Or Less: 2 Small Biotechs Moving On News
Seeking Alpha
Wed, 07/2/14 - 01:12 pm
Pixuvri
Agenus
Cell Therapeutics
Cell Therapeutics Regains Rights to Two In-Development Cancer Medicines
Wall St Cheat Sheet
Mon, 01/13/14 - 05:03 pm
Cell Therapeutics
Novartis
Opaxio
Pixuvri
Cell Therapeutics' aggressive non-hodgkin lymphoma treatment wins market access in France
Pharmaceutical Business Review
Mon, 08/19/13 - 09:54 am
non-Hodgkin's lymphoma
France
Cell Therapeutics
Pixuvri
German Institute for Quality and Efficiency in Health Care (IQWiG) Publishes Dossier Evaluation within Early Benefit Assessment Process of Pixuvri (pixantrone)
Yahoo/PR Newswire
Sat, 03/2/13 - 03:56 pm
Pixuvri
non-Hodgkin B-cell lymphoma
non-Hodgkin's lymphoma
Cell Therapeutics
Cell Therapeutics: European Revenue Opportunity Could Represent A Turning Point
Seeking Alpha
Fri, 09/28/12 - 12:02 pm
Cell Therapeutics
Europe
Pixuvri
non-Hodgkin B-cell lymphoma
Cell Therapeutics soars 24% on EU drug launch
Marketwatch
Tue, 09/11/12 - 01:25 pm
Europe
Cell Therapeutics
Pixuvri
non-Hodgkin's lymphoma
Drug Approval! Oh, Wait, We Knew That Already.
Motley Fool
Mon, 05/14/12 - 11:15 am
drug approvals
Cell Therapeutics
Pixuvri
non-Hodgkin B-cell lymphoma
Europe
FDA Pharma Meetings for February
Motley Fool
Tue, 01/31/12 - 07:58 am
FDA
Amgen
Xgeva
Cell Therapeutics
Pixuvri
Vivus
Qnexa
Chelsea Therapeutics
Northera
Cell Therapeutics appeals FDA decision on Pixuvir
Yahoo/AP
Sat, 12/4/10 - 12:02 pm
Cell Therapeutics
Pixuvri
non-Hodgkin's lymphoma
Cell Therapeutics’ drug moves ahead in Europe
Bizjournals.com
Wed, 11/17/10 - 01:07 pm
Europe
Cell Therapeutics
pixantrone
Pixuvri
Seven Biotech Drugs to Watch in the Second Quarter
BNET Pharma
Tue, 04/13/10 - 10:35 am
Acorda Therapeutics
AMPYRA
Cell Therapeutics
pixantrone
Pixuvri
Dendreon
Provenge
InterMune
Esbriet
Pozen
Vimovo
XenoPort
Horizant
Astellas
OSI Pharmaceuticals
Ironwood
Cell's Pixantrone Denied Approval
Yahoo/Zacks
Sat, 04/10/10 - 11:41 am
Cell Therapeutics
Pixuvri
non-Hodgkin's lymphoma